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Abstract Introduction
Genes of interest can be targeted specifically to respiratory
epithelial cells in intact animals with high efficiency by ex-
ploiting the receptor-mediated endocytosis of the polymeric
immunoglobulin receptor. A DNA carrier, consisting of the
Fab portion of polyclonal antibodies raised against rat secre-
tory component covalently linked to poly-L-lysine, was used
to introduce plasmids containing different reporter genes
into airway epithelial cells in vivo. We observed significant
levels of luciferase enzyme activity in protein extracts from
the liver and lung, achieving maximum values of
13,795+4,431 and 346,954±199,120 integrated light units
(RLU) per milligram of protein extract, respectively. No
luciferase activity was detected in spleen or heart, which
do not express the receptor. Transfections using complexes
consisting of an irrelevant plasmid (pCMV lacZ) bound to
the bona fide carrier or the expression plasmid (pGEMluc)
bound to a carrier based on an irrelevant Fab fragment
resulted in background levels of luciferase activity in all
tissues examined. Thus, only tissues that contain cells bear-
ing the polymeric immunoglobulin receptor are transfected,
and transfection cannot be attributed to the nonspecific up-
take of an irrelevant carrier-DNA complex. Specific mRNA
from the luciferase gene was also detected in the lungs of
transfected animals. To determine which cells in the lung are
transfected by this method, DNA complexes were prepared
containing expression plasmids with genes encoding the bac-
terial 8-galactosidase or the human interleukin 2 receptor.
Expression of these genes was localized to the surface epithe-
lium of the airways and the submucosal glands, and not the
bronchioles and alveoli. Receptor-mediated endocytosis can
be used to introduce functional genes into the respiratory
epithelium of rats, and may be a useful technique for gene
therapy targeting the lung. (J. Clin. Invest. 1995. 95:493-
502.) Key words: polymeric immunoglobulin receptor * se-
cretory component * trachea * epithelial cells * gene transfer
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The respiratory epithelium is the primary target tissue for gene
therapy of cystic fibrosis, and several methods of gene transfer
permit the introduction of functional genes into cells of the
respiratory tract in animals. Receptor-mediated gene transfer
has particular appeal for it may provide a noninfectious method
for delivering DNA to specific target cells. This method exploits
the process of receptor-mediated endocytosis to introduce DNA
exclusively into cells that bear the target receptor. The plasmid
DNA transferred in this manner can be of considerable size
(1), thus permitting flexibility not only in the selection of the
transgene but also in the choice of promoter and enhancer ele-
ments. The delivery of exogenous DNA using receptor-medi-
ated systems depends on the stability of the carrier-DNA com-
plex, the presence and number of receptors on the surface of
the targeted cell, the receptor-ligand affinity and interaction,
and efficient internalization of the complex (2, 3). Furthermore,
the transferred genes must escape from endosomes (4, 5) and
traffic to the target cell's nucleus. This strategy has been used
to introduce reporter genes into cells in culture, and results
in transient but high levels of expression from the transgene.
However, receptor-mediated gene transfer systems have pro-
duced variable results in vivo. The transgene is expressed for
a short time at low levels (6, 7) unless invasive manipulation
of the animal, such as partial hepatectomy, is performed (8-
10). However, Perales and colleagues (11 ) have recently
shown that surgical manipulation of the liver was not necessary
for prolonged expression of transgenes introducted into hepato-
cytes via the asialoglycoprotein receptor. For airway epithelial
cells, adenovirus-polylysine and transferrin-adenovirus-polyly-
sine vectors achieved high efficiency transfection of cells in
culture (1, 5). However, when the same conjugates were used
to introduce exogenous genes into cotton rats via the intratra-
cheal route, the transgene was transiently expressed at low
levels ( 12).
We have demonstrated that in primary cultures of human
tracheal epithelial cells, targeting the polymeric immunoglobu-
lin receptor (pIgR)' can be used for the specific delivery of
reporter genes to cells that bear the receptor (2). This receptor
undergoes efficient internalization and is specifically adapted
for the nondegradative transfer of large molecules. In addition,
the cellular distribution ofpIgR expression in the surface epithe-
lium and serous cells of the submucosal glands conforms to
that of the cystic fibrosis transmembrane conductance regulator
in human airways (13, 14). In this report, we show that tar-
1. Abbreviations used in this paper: IL2r, human interleukin 2 recep-
tor; pIgR, polymeric immunoglobulin receptor; SC, secretory compo-
nent; SPDP, N-Succinimidyl 3-(2-pyridyldithio) proprionate; X-gal, 5-
Bromo4-chloro-3-indolyl-,8-galactopyranoside.
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geting the pIgR in rats results in significant expression of the
transgene in tissues that contain receptor-bearing cells, which
was maximal 6 d after transfection.
Methods
Materials. DNA-modifying enzymes, nucleotides, and 5-Bromo-4-
chloro-3-indolyl-,6-D-galactopyranoside were purchased from Boeh-
ringer Mannheim (Indianapolis, IN). GeneScreen Plus and [a 32p] dCTP
were obtained from DuPont-New England Nuclear (Boston, MA). Pro-
tein A MAPS agarose columns were purchased from Bio Rad (Rich-
mond, CA). Papain and poly-L-lysine were obtained from Sigma Chemi-
cal Co. (St. Louis, MO), and N-Succinimidyl-3-(2-pyridyldithio)pro-
prionate was purchased from Pierce Chemical Co. (Rockford, IL).
Promega (Madison, WI) assay reagents were used to measure luciferase
activity. Reverse transcriptase and polymerase chain reaction reagents
were obtained from Perkin Elmer Cetus (Norwalk, CT). The mouse
monoclonal anti-interleukin 2 receptor antibody was obtained from Dako
Corp. (Carpenteria, CA).
Production of carrier-DNA complexes that target the polymeric
immunoglobulin receptor. Two features of this system are critical for
the successful introduction of genes into the airway epithelial cells: (a)
anti-secretory component (SC) Fab antibodies serve as the targeting
ligand in this gene transfer system, which permits specific delivery of
genes to cells that express pIgR; and (b) the condensation of the DNA
by the anti-SC Fab-based carrier into highly compact complexes suitable
for efficient uptake via an endocytic pathway.
Preparation of Fab antibody fragments. Polyclonal antisera were
raised in rabbits against SC purified from rat bile (15). The antibody
recognizes purified SC, secretory IgA, and the pIgR, but not dimeric
IgA. The antiserum was stored in l-ml aliquots at -20TC until the
immunoglobulin G (IgG) was isolated. The antibody was isolated by
Protein A MAPS agarose chromatography as described by the manufac-
turer. Fab fragments were prepared and isolated as described previously
for the anti-human SC Fab-based carrier (2). Briefly, 2 mg of isolated
IgG was treated with 20 jig of insoluble papain attached to agarose
beads for 12 h at 37°C in the presence of 100 mM sodium acetate (pH
5.5) 50mM cysteine, and 1 mM EDTA. The Fab fragment was separated
from intact antibody and Fc fragments by Protein A chromatography.
An irrelevant Fab was generated by papain digestion of IgG from pre-
immune rabbit serum. Cleavage of the IgG was verified by separating
the digestion products using SDS-PAGE. The Fab product migrated as
a band at 52 kD.
Preparation of the anti-SC Fab-polylysine carrier. The Fab frag-
ment of the anti-SC antibody was covalently linked to poly-L-lysine
(average M, = 20 kD) using the heterobifunctional cross-linking reagent
N-Succinimidyl 3-(2-pyridyldithio) proprionate (SPDP) (16); 2.5 /1
of 20 mM SPDP in absolute ethanol was incubated with the anti-SC
Fab fragment (200 Ig) in 0.1 M phosphate buffered saline (PBS), pH
7.5, at 22°C for 60 min. After introduction of 2-pyridyl disulfide struc-
tures onto the Fab fragment, unreacted SPDP and low molecular weight
reaction products were removed by dialysis. The disulfide bridges of
the modified Fab fragment were cleaved with 25 mM DTT, pH 4.5. 15-
fold molar excess of poly-L-lysine and SPDP relative to the modified
Fab fragment were added, and the reaction was carried out at 22°C for
24 h. The conjugate was dialyzed to remove low molecular weight
reaction products, and analyzed by separating the resultant proteins
using 0.1% SDS-7.5% PAGE. These gels showed a broad band that
migrated at > 200 kD (data not shown). This slow migration is most
likely due to the high proportion of basic amino acids, i.e., lysine,
attached to the Fab fragment. A fraction of the Fab fragment did not
conjugate to the poly-L-lysine.
Formation of the anti-SC Fab carrier-based DNA complexes. The
carrier-DNA complexes were formed using a general technique pre-
viously described for a galactosylated polylysine ligand ( 11), a method
different from that used in our previous work targeting the pIgR in
vitro (2). The conditions necessary to ensure condensation of the DNA
depend on a number of variables, including the size, sequence and
physical state of the DNA, the chain length of the poly-L-lysine, and
the nature of the ligand. The optimal concentration of sodium chloride
required to effectively compact the plasmid is also dependent on these
variables (11 ).
DNA was condensed by the slow addition of the anti-SC Fab carrier
in the presence of 400 mM sodium chloride and constant vortexing for
30 min at room temperature. After the addition of the carrier to the
DNA, the sodium chloride concentration in the solution was adjusted
by adding 3-t1t aliquots of 5 M NaCl. As the ionic strength of the
solution was increased, the anti-SC Fab-polylysine-DNA complexes
proceeded from an aggregated to a condensed state, and the turbidity
of the mixture cleared ( 11). The final volume of the solutions was 300-
500 y1, and contained 300 ,/.g of plasmid DNA in 470-650 mM NaCl.
Different final concentrations of sodium chloride in different prepara-
tions of the complexes was primarily due to heterogeneity in size of the
poly-L-lysine component of the carrier. Based on our previous experi-
ments (11), the optimal charge ratio of the DNA phosphate groups to
lysine was approximately 1:0.7. The condensation process was moni-
tored by circular dichroism spectroscopy and electron micros-
copy (11).
The expression plasmid pGL2 (Promega) contained the SV40 viral
promoter and enhancer ligated to the Photinus pyralis luciferase gene,
and inserted into the Escherichia coli pUC19 vector. The plasmids
pCMV lacZ (17) and pCMVIL2r (Saulino, A., and M. L. Drumm,
unpublished data), consisting of the cytomegalovirus (CMV) promoter
linked to the E. coli P3-galactosidase lacZ and the interleukin 2 receptor
(IL2r) genes, respectively, were also used as reporter genes. For studies
of luciferase activity, these plasmids were used as irrelevant DNA
(IDNA) controls. The plasmids were grown in E. coli DH5a, purified
on a cesium chloride gradient using standard techniques (18), and
treated with RNaseA and T1. No contamination with bacterial genomic
DNA or RNA was detected by 1.0% agarose gel electrophoresis of
the plasmid preparations. Digestions of the plasmids with restriction
endonucleases yielded the appropriate size DNA fragments. The sizes
of plasmids are as follows: pGL2, 6.0 kb; pCMV lacZ, 10.9 kB; and
pCMVIL2r, 5.4 kB.
Animals. The anti-rat SC Fab-polylysine carrier was used to transfer
reporter genes into the airways and livers of intact animals. Adult, male
Sprague-Dawley rats, weighing approximately 250 g, were anesthetized.
Using aseptic technique, 0.3-0.5 ml of a solution containing 300 jig of
an expression plasmid complexed to the carrier was injected slowly (1
min) into the caudal vena cava. All animals injected with the complexes
survived. The rats were killed at different times after infusion of the
complexes and various organs were removed for analysis. Mock trans-
fections of animals using DNA complexes consisting of an irrelevant
plasmid bound to the carrier or the expression plasmid bound to a carrier
made with an irrelevant Fab fragment were also performed in parallel.
The animal research protocol was reviewed and approved by the Case
Western Reserve University Institutional Animal Care Committee.
Detection of the exogenous plasmid DNA using the polymerase
chain reaction. One microgram of genomic DNA isolated from the
lungs of transfected and nontransfected rats 6 d after treatment was
amplified as described by the manufacturer. After incubating the solution
at 94°C for seven minutes to denature the genomic DNA, the DNA was
amplified through 25 cycles, using the following primers for the lucifer-
ase gene: AGACGAACACYTCTICATAGTFGACC (luc I), a primer
that bind to the 5' end of the luciferase gene corresponding to positions
1551 to 1576, and TTfCCTCATTAAAGGCATTCCACC (luc H), an
antisense primer that corresponds to nucleotide positions 2260 and 2283.
The predicted length of the amplified region of DNA was 732 base
pairs. 10 ml of amplified DNA was separated by electrophoresis using
a 1.6% agarose gel, transferred to a nitrocellulose filter, and analyzed
by Southern blot hybridization with a radiolabeled cDNA probe specific
for the luciferase gene.
Detection of luciferase mRNA using the polymerase chain reaction.
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The presence ofmRNA transcripts from the luciferase gene in the lungs
of rats was determined 6 and 12 d after transfection by treatment of
total cellular RNA with Moloney Murine Leukemia Virus reverse tran-
scriptase and amplification of the resultant cDNA by the polymerase
chain reaction. Briefly, 1 jg of total rat liver RNA was added to a
solution containing 500 nM of (dT)16 oligonucleotide primer and 500
nM of each deoxynucleotide triphosphate, and heated to 420C for 2 min.
Reverse transcriptase was added, the mixture was incubated for 30 min
at 420C, and 1 j1 of the cDNA pool was amplified by the polymerase
chain reaction, using primers within the chimeric luciferase gene de-
scribed above. Because of the presence of an intron 66 base pairs in
length, the sizes of the amplified sequences from plasmid DNA and
cDNA generated from RNA after treatment with reverse transcriptase
are different, which distinguished transferred DNA from mRNA tran-
scribed from the transgene. The expected length of the amplified cDNA
from the luciferase mRNA was 666 bp. As a control, rat glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA was also amplified us-
ing similar conditions with primer CCATGGAGAAGGCTGGGGC
(GAPDH 5'), which corresponds to positions 371 to 389 in the GAPDH
gene, and primer CAAAGTTGTCATGGATGACC (GAPDH 3'), an
antisense primer which corresponds to positions 546 to 565. The ex-
pected size of the amplified cDNA generated from the rat GAPDH
mRNA was 194 base pairs. The RNA isolated from lungs of transfected
and nontransfected rats was evaluated. In addition, the same RNA sam-
ples not converted to cDNA by reverse transcriptase were used as poly-
merase chain reaction templates as controls to establish that contaminat-
ing plasmid DNA had not been amplified. The products were separated
by agarose gel electrophoresis and their identity verified by Southern
blot hybridization using a radiolabelled luciferase or glyceraldehyde-3-
phosphate dehydrogenase DNA probes.
Cytochemical assay for fB-galactosidase activity. Individual cells
expressing ,6-galactosidase in tissues were identified after incubation
with 5-Bromo-4-chloro-3-indolyl-,j-galactopyranoside (X-gal). Briefly,
the cells were fixed with a solution of 0.5% glutaraldehyde in PBS for
10 min, washed twice with PBS, pH 7.5, and then incubated with a
solution containing 0.5% X-gal dissolved in N-N-dimethylformamide,
5 mM potassium ferricyanate, 5 mM potassium ferrocyanide, and 1 mM
magnesium chloride in PBS (pH 7.4) for 4 h at 37°C. After incubation,
the tissues were fixed in 2% para formaldehyde/0.5% glutaraldehyde
in PBS overnight at 40C, paraffin embedded, and cut into 5-jIm sections.
The sections were counter-stained with nuclear fast red, and blue colored
cells were identified by light microscopy. In addition, adjacent sections
were stained with Alcian blue (pH 2.5)/periodic acid Schiff or hematox-
ylin/eosin using standard protocols (19).
Immunohistochemical staining for the interleukin 2 receptor. The
expression of the transgene in tissues transfected with the plasmid
pCMVIL2r was determined by indirect immunofluorescence. Frozen
sections (10 jm) of trachea were fixed with acetone for 10 min at
-20°C and treated with 0.5% sodium borohydride in water for 10 min
at 22°C to reduce autofluorescence. The sections were then incubated
sequentially with a mouse monoclonal anti-interleukin 2 receptor anti-
body for 1 h at 370C, then fluorescein isothiocyanate-conjugated goat
anti-mouse IgG for 1 h at 37°C. Both the primary and secondary anti-
bodies were diluted 1:100 in PBS, and between each incubation the
slides were washed three times for 5 min with PBS, pH 7.5. The stained
tissue sections were examined by fluorescence microscopy using an
inverted Zeiss epifluorescence microscope and emitted light was de-
tected by a cooled CCD camera.
Assays for luciferase activity. Tissues were harvested from
transfected and control rats after the animals were sacrificed and per-
fused in situ with cold PBS, pH 7.5, for 5 min. The tissues were homoge-
nized in lysis buffer (Promega) and permitted to incubate at 220C for
10 min. These lysates were centrifuged for 5 min at 4°C, and the superna-
tants were analyzed for luciferase activity. The lysates were assayed for
protein content using the Bradford method and the measured integrated
light units (10 s interval) were standardized for total protein content
(20). All measurements were performed in triplicate and expressed as
an average of the values.
Immunohistochemical staining of rat tracheasforplgR. The expres-
sion of pIgR in rat tracheal epithelial cells was determined by indirect
immunofluorescence. Tracheal sections were frozen then fixed with ace-
tone at -20'C for 10 min, and incubated sequentially with rabbit anti-
rat SC for 1 h at 370C, then rhodamine-conjugated goat anti-rabbit IgG
for 1 h at 37°C. Both antibodies were diluted 1:100 in PBS, pH 7.5.
Between each incubation, the slides were washed three times with PBS,
pH 7.5. The stained tissues were examined by fluorescence microscopy
as described above.
Statistical analysis. Data are expressed as means±standard error of
the mean (SEM), and evaluated by a nonparametric analysis of variance
using the Kruskall-Wallis test (21).
Results
Construction of the anti-secretory component Fab antibody-
based carrier-DNA complexes. An essential step in the assembly
of a carrier-DNA complex capable of efficient gene transfer
in animals is the condensation of the plasmid DNA to a size
and shape suitable for uptake via an endocytic pathway. Perales
and colleagues ( 11) described a procedure for condensation
of individual DNA molecules into unimolecular complexes of
defined structure by adjusting the charge neutralization of the
DNA by the slow addition of ligand-polylysine conjugates in
the presence of high concentrations of sodium chloride. This
technique permits a change in the conformation of the DNA
molecule allowing the flexible polymer to bend and become
more compact. This condensation process is monitored by circu-
lar dichroism spectroscopy and by electron microscopy of the
DNA complexes. As shown in the electron photomicrographs
in Fig. 1, complexes made using the anti-rat SC Fab-polylysine
carrier are compact toroids approximately 25 nm in diameter.
Small circular structures measuring 1 nm in diameter were
noted in preparations of both the complexes and the conjugate
alone, and most likely represents the anti-SC Fab-polylysine
carrier. In comparison, a carrier consisting of galactosylated
polylysine condensed individual DNA molecules into toroid
structures measuring 10-12 nm in diameter (11).
In vivo transfection using the anti-secretory component Fab
antibody-polylysine carrier. We tested the transfer of reporter
genes into the airway epithelium in vivo by the systemic injec-
tion of a targeting complex consisting of the Fab portion of
IgG directed against rat SC, the extracellular domain of pIgR,
conjugated to poly-L-lysine, and noncovalently bound to re-
porter genes. The results of luciferase assays performed 6 d
after infusion of the complexes in tissue homogenates extracted
from liver, lungs, spleen, and heart are shown in Fig. 2. In
animals injected with the anti-rat SC Fab-polylysine carrier-
DNA complex, we observed transgene expression in protein
extracts from the liver and lungs, but not from the spleen and
heart, tissues that do not express the pIgR (22). Furthermore,
animals treated with the complexes prepared with an irrelevant
plasmid (pCMVlacZ) bound to the bona fide carrier, or the
expression plasmid (pGL2) bound to a carrier prepared with
an irrelevant Fab fragment had no significant luciferase activity
in any tissue examined. Tissues from animals injected with a
mixture of the individual, nonconjugated components of the
complex (not conjugated) also did not have transgene expres-
sion (data not shown). Thus, only tissues that contain cells
bearing pIgR are transfected by our procedure, and DNA uptake
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Figure 1. Electron micrograph of the anti-rat SC Fab-polylysine camrer-DNA complex. The anti-rat SC Fab-polylysine carrier-DNA complexes
were formed as descnibed mn Methods, and a drop of the solution was mimmediately added to a 1,000-mesh electron microscope carbon grid, blotted,
and stained with 0.04% uranyl acetate. The samples were diluted in water (1:40) before preparation for electron microscopy. The carrier-DNA
complexes were examined using a JEOL- IOOC electron microscope, and are indicated in the photomicrograph by large arrowheads. For comparison,
an electron micrograph of complexes made with the galactose-terminal glycoprotein carrier is shown. Complexes made using the anti-rat SC Fab-
polylysine carrier appeared as toroid structures -~25 nm. in diameter; the smaller circular structures (small arrowhead) most likely represent the
anti-SC Fab-polylysine carrier (. 1 nm in diameter). Bar, 25 nm.
cannot be attributed to nonspecific introduction of an irrelevant
Fab antibody-based complex.
The time course of luciferase expression is illustrated in
Fig. 3. The maximum levels of luciferase activity was detected
in the liver 4 d and lung 6 d after transfection, and achieved
values of 13,795±4,431 and 346,954±199,120 integrated light
units (ILU) per milligram of protein extract, respectively, that
were statistically different than nontransfected controls. Again,
spleen and heart did not have appreciable transgene expression
(data not shown). Luciferase activity decreased to - 1% of
maximum values by day 12 (Fig. 3).
The transgene was detected in the lungs of animals 12 d
after transfection by polymerase chain reaction amplification
using primers specific for the luciferase gene (Fig. 4 a). Ampli-
fication of DNA extracted from the lungs of nontransfected and
mock-transfected rats did not demonstrate the transferred gene.
Furthermore, the mRNA transcripts from the luciferase gene
were detected in the lungs of rats after transfection by treating
total cellular RNA with reverse transcriptase and amplifying the
cDNA by the polymerase chain reaction, using oligonucleotide
primers specific for the luciferase gene. All RNA samples were
evaluated in the presence and absence of reverse transcriptase
to further ensure that contamination with plasmid DNA had not
occurred. As shown in Fig. 4 b, luciferase transcripts were
detected in the lungs of rats as long as 12 d after transfection,
but not in nontransfected animals. No luciferase mRNA tran-
scripts were noted in the absence of reverse transcriptase. As a
control, mRNA from the endogenous GAPDH gene was identi-
fied in all of the corresponding samples (data not shown)
The tissue and cellular distribution of the transgene expres-
sion were examined in tissue sections from animals injected
with other reporter genes. 3 d after the injection of complexes
containing pCMV lacZ, tissue sections of trachea, lung, and
liver underwent cytochemical staining for fl-galactosidase activ-
ity. An animal treated with complexes made using an irrelevant
plasmid (pCMVIL2r) served as a control, and no blue-stained
cells were detected in the tracheal epithelium or submucosal
glands (Fig. 5 a). As shown in Fig. 5 b, expression of the
transgene in the trachea was limited generally to the cells lining
the epithelial surface. Six different tracheal sections and a total
of 2464 cells were examined, and an average of 17.7% of the
tracheal epithelial cells stained blue. Expression ranged from
10.9 to 27.7% of the airway epithelial cells in different sections.
Although the staining appears to be localized to the apices
of the tracheal epithelial cells at lower magnifications, higher
magnification demonstrates blue staining throughout the cyto-
plasm conforming to the shape of the cell (Fig. 5 c). Both
ciliated and secretory (goblet) respiratory epithelial cells ex-
pressed ,/-galactosidase, and blue-stained cells were also identi-
fied in the submucosal glands (Fig. 5 d). However, transfection
efficiency of the submucosal glands was difficult to determine
accurately because few glands were found in sections of the
proximal trachea. No expression from the transgene was de-
tected in the terminal or respiratory bronchioles, or in the alveo-
lar pneumocytes (data not shown).
The expression of /3-galactosidase parallels the distribution
of pIgR in the rat and human airway. As illustrated in Fig. 6,
the pIgR was detected in the surface epithelium and submucosal
glands of rat trachea, but not in alveoli. Confirmatory studies
using the human IL2r, a surface protein that has been used as
a reporter in the transduction of respiratory epithelial cells in
vitro (23), as a reporter gene demonstrated that transgene ex-
pression was specifically localized in the airway epithelium.
Immunofluorescence was specifically localized to the apical sur-
face of numerous respiratory epithelial cells from the animal
transfected with the plasmid pCMVIL2r (data not shown),
which was absent from the airway epithelia of nontransfected
rats or animals transfected with pCMV lacZ (data not shown).
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Figure 2. Tissue specificity and expression of pGEMluc introduced into
rats using the anti-rat SC Fab-polylysine carrier. The plasmid pGL2
(300 IHg) complexed to the anti-rat SC Fab-based carrier was infused
into the caudal vena cava of rats (Transfected, n = 4). 6 d after injection
the animals were killed and protein extracts from the spleen, heart, liver,
and lung were assayed for luciferase activity. Animals treated with
complexes consisting of the expression plasmid (pGL2) bound to a
carrier made with irrelevant antibodies (IFab, n = 2) or an irrelevant
plasmid (pCMV lacZ) bound to the authentic carrier (IDNA, n = 3)
were used as controls. Protein extracts from nontransfected rats (Non-
transfected, n = 3) were analyzed in parallel. Luciferase activity is
expressed as integrated light units per milligram of total protein derived
from cell lysates. Data are reported as mean±SEM, and evaluated by
a nonparametric analysis of variance using the Kruskall-Wallis test. The
level detected in the transfected lung was statistically different than
nontransfected controls (P < 0.05).
Thus, expression in airways is observed whether the reporter
gene is luciferase, f3-galactosidase, or the human interleukin 2
receptor. In the liver, rare (< 1%), blue-stained hepatocytes
were observed in animals transfected with pCMV lacZ, but not
in either non-transfected or mock-transfected rats (data not
shown).
Discussion
We report the successful transfer of reporter genes conjugated
to anti-rat SC Fab-polylysine carrier into the airway epithelium
in vivo. This technique specifically delivered the transgene to
the liver and lung, tissues in which this receptor is expressed.
Tissues that do not express the pIgR, spleen and heart, were
not transfected. In addition, neither a conjugate prepared with
irrelevant Fab fragments nor a complex prepared with a plasmid
containing an irrelevant reporter gene produced detectable
transgene activity. Thus, this complex specifically targets pIgR-
bearing tissues. The presence of the receptor's natural ligands,
polymeric IgA and IgM, does not appear to prevent the uptake
of the transgene in vivo. Transgene expression in tissues that
contain receptor-bearing cells was maximal at 6 d after transfec-
tion, decreased to lower levels at 12 d, and had virtually disap-
peared by eighteen days.
Several approaches permit the introduction of functional
genes into cells of the respiratory tract in vivo, including replica-
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Figure 3. Duration of transgene expression after introduction into the
livers and lungs of rats using the anti-rat SC Fab-polylysine carrier. In
four separate experiments, 300 lsg of the plasmid pGL2 complexed to
the anti-rat secretory component Fab antibody-carrier was infused into
the caudal vena cava of rats. Animals were killed 2 (n = 3), 4 (n = 3),
6 (n = 4), 8 (n = 2), 12 (n = 3), and 18 (n = 2) d after injection,
and cell lysates from the liver and lung were assayed for luciferase
expression. Protein extracts obtained from the livers and lungs of three
untreated rats were used as controls. Data are reported as mean±SEM,
and evaluated by a nonparametric analysis of variance using the
Kruskall-Wallis test. Luciferase activity detected in the liver 4 d and
the lung 4 and 6 d after transfection were statistically different than
nontransfected controls (P < 0.05). (Open columns) Protein extracts
from lung; (solid columns) protein extracts from liver.
tion deficient, recombinant adenoviruses (24-27), adeno-asso-
ciated virus (28-30), and liposomes (31-35). Receptor-medi-
ated gene transfer offers a large packaging capacity of genes
and tissue specificity, and receptors other than pIgR have been
used to target the airway. Reporter genes have been introduced
into airway epithelia of intact animals using adenovirus-polyly-
sine and human transferrin-adenovirus-polylysine carriers ( 12).
In these experiments, disabled adenovirus served as both a li-
gand and an endosomolytic agent. Intratracheal instillation of
DNA bound to these conjugates resulted in transient expression
of the reporter gene which peaked 1 d after transfection and
returned to pretreatment levels by 7 d. However, we cannot
directly compare the efficiency of the human transferrin-adeno-
virus-polylysine conjugates with the anti-SC Fab antibody-poly-
lysine carrier. Differences in the route of administration, quan-
tity of plasmid DNA delivered, and the specific cells and tissues
targeted preclude such comparisons.
Receptor-mediated gene transfer via the pIgR has the benefit
of being a noninfectious vector, specific for the targeted cells,
that results in a significant level and duration of transgene ex-
pression. Specificity of delivery of corrective genes to affected
cells may be important for gene therapy, since indiscriminate
transgene expression may have detrimental effects. For exam-
ple, the expression of the cystic fibrosis transmembrane conduc-
tance regulator in fibroblasts leads to dose-dependent growth
inhibition (36). Moreover, this system permits the delivery of
functional genes from the circulation. This ability of the anti-
SC Fab-based carrier to transfect only epithelial and submucosal
gland cells in the airways may be an important advantage, since
the approach from the blood may permit more uniform distribu-
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Figure 4. Presence and expression of the luciferase
a. Luciferase DNA b. Luciferase mRNA gene in the lungs of rats following transfection using
receptor-mediated gene transfer. (a) 1 jig of DNA
~~~~~~Vo o 0 oCD) co rmlnso hert Ln Td a mlfe
o z z using primers specific for the luciferase gene by PCR,
CI) M CD CD CD M CD CD CD c CDcm transferred to a nitrocellulose filter, and hybridized
3 3 3 3 3 M 3 3 3 3 3 n to a radiolabeled luciferase cDNA probe. For compar-
_j 3 _j _j _J _I _J _j _J _J _J _J
1033 bp ison, a sterile water (Control) and DNA isolated from
0b6-732 bp the lung of a nontransfected animal (Lung NT) were
also amplified. (b) Total cellular RNA extracted from
453 bp the lungs of two rats 6 (Lung T6d), 12 (Lung TJ2d),
18 (Lung T18d), and 36 (Lung T36d) d after transfec-
tion were treated with (RT+) or without (RT-) re-
Reverse Transcriptase + Reverse Transcriptase verse transcriptase. Total cellularRNA from the lungs
(Lung NT) of two nontransfected animal were used
as controls. Using primers specific for the genes encoding luciferase, the resultant cDNA were amplified by PCR. The reaction products were
separated by agarose gel electrophoresis, and analyzed by Southern blot hybridization using luciferase radiolabelled cDNA probes. The blots were
exposed to radiographic film for 16 h.
tion of the vector than delivery via the airway and could facili-
tate the approach to the submucosal glands.
Other important considerations for gene therapy are the ex-
tent and level of expression of the transgene. Studies in vitro
suggest that correction of as few as 6% of cells in a cystic
fibrosis epithelium with the cystic fibrosis transmembrane con-
ductance regulator will produce electrophysiologic correction
of the monolayer (23). By this criterion, targeting the pIgR
may transfect a sufficient number of cells in the airway to be
practical for treatment of cystic fibrosis. However, the determi-
nants of the level of transgene expression in the different pIgR-
expressing tissues are so far unclear from our studies. Maximal
luciferase activity was an order of magnitude higher in tissue
homogeunates from the lung than in the liver, a difference all
the more striking when one considers that most of the cells in
the rodent liver, the hepatocytes, express the pIgR, whereas this
receptor is expressed in few cells in the lung and respiratory
tract (only epithelial cells in the large and medium sized air-
ways). The data for luciferase expression are concordant with
the expression of the lacZ transgene, which demonstrated rare
hepatocytes positive for,-galactosidase activity while a sig-
nificant number of airway epithelial cells showed a robust blue
color after cytochemical staining. Because the data are consis-
tent for two reporter genes (luciferase and lacZ) driven by two
different promoters (SV40 and CMV regulatory elements), this
difference may be less likely to be due to relative promoter
strength or differences in protein processing in the two tissues.
Nevertheless, marked variations have been observed in the ex-
pression of transgenes driven by viral promoter and enhancer
elements in different tissues in transgenic animals (37, 38).
Several additional explanations for this difference in
transgene expression are possible, including unequal levels of
expression of the receptor, competition from the natural ligand,
or the trafficking of the DNA-carrier complex in the particular
cell. In rodents, pIgR expression, based on the production of
SC, is significantly greater in the liver than lung (39). Radiola-
beled dIgA injected into the systemic circulation of rats is trans-
ported from blood to bile over 20 times more rapidly than it is
transported into the airways (40). The efficient transcytosis
which is prominent in hepatocytes may permit rapid transit of
the complexes through hepatocytes, with little time to escape
the endosome and be expressed. If transcytosis is less rapid in
the airway, more of the carrier-DNA complex might escape
from the transcytotic vesicles. The vascular distribution and
clearance of anti-SC Fab antibodies may be different from the
natural ligand. Finally, the relative efficiency of binding and
trafficking of these antibodies in hepatocytes compared to respi-
ratory epithelial cells has not been determined. Several of these
possibilities can be tested experimentally.
No attempts were made to treat the airway epithelium to
augment or prolong transgene expression in this study. Even
so, in contrast to previous studies in which the airways were
targeted by the transferrin receptor (12), transgene expression
lasted for > 8 d without specific enhancement. This success
may be attributable to the particular receptor being targeted or
to the highly condensed form of the plasmid in the carrier-
DNA complex, which is smaller than others described in the
literature (41). Since we have observed prolonged expression
of transgenes in hepatocytes delivered using a galactosylated
polylysine carrier (11), we believe that the compacted form
of the plasmid contributes to the survival and the protracted
expression of the transferred gene. This preparation of highly
condensed DNA complexes using the anti-rat SC Fab-based
carrier was different from that described in our previous work
with the anti-human SC Fab-polylysine (2), and was patterned
after the method of condensation we used for experiments to
target the asialoglycoprotein receptor (11), though the exact
concentrations of sodium chloride were different from those
used with galactosylated polylysine carrier. Complexes made
using the anti-SC Fab carrier-DNA complex were larger than
those containing galactose-terminal glycoprotein (11), as
judged by electron microscopy, most likely due to the effects
of the Fab fragment on the interaction of the polycation and
DNA, but are still substantially smaller than other reported com-
plexes (41). The size of the complexes can be important be-
cause many endocytotic receptors discriminate against ligands
of a determined size range in vivo (42, 43). We expect that
the pIgR, however, can accommodate larger complexes than
the asialoglycoprotein receptor. Indeed, the pIgR is adapted
for the uptake of large, multimeric molecules, and immune
complexes formed with its natural ligand can be efficiently
internalized (44).
The size and structure of the complexes may also be im-
portant for its stability in the blood, receptor-ligand interaction,
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Figure S. Photomicrographs of rat tracheal epithelial celis transfected with pCMVlacZ using the anti-rat secretoly component Fab antibody-
polylysine carrier. 300 osg of the plasmid pCMV lacZ (b-d) or pCMVI1L2r (a) complexed to the anti-rat SC Fab-based carrier was infused into
the caudal vena cava of rats. After 3 d, the tissue sections were fixed and stained with a solution containing 0.5% X-gal as described in Methods.
Original magnifications of the photomicrograplis are in parentheses. The airway epithelium (E) and submucosal glands (G) are shown, and blue-
stained cells are indicated by arrowheads. (a) Brighffield view of tracheal epithelial cells and submucosal glands from a rat after transfection with
the plasmid pCMVIL2r and cytochemical staining with X-gal and counter-staining with nuclear fast red (x 1I00). (b) Brightfield view of tracheal
epithelial cells after transfection with the plasmid pCMV lacZ and cytochemical staining with X-gal (x 1I00). (c) Higher magnification (X400) of
the epithelial cells of the trachea of a transfected rat. Distinct, blue staining is visible throughout the cytoplasm in the transfected epithelial cells.
(d) Higher magnification (x400) of submucosal glands in sections from the proximal trachea of a transfected rat. Isolated, blue stained cells were
observed in several of the epithelial cells and submucosal glands.
internalization, and resistance to endonuclease degradation of the DNA complex is dependent on several variables, includ-
(45). Moreover, the polylysine component of the carrier may ing the concentration of sodium chloride, length of the polyly-
assist in nuclear trafficking of the DNA, since the sequences sine, as well as the size, sequence, and state of the DNA (48,
responsible for the translocation of viral proteins into the nu- 49). Nevertheless, despite improvements in the production of
cleus are rich in lysine (46, 47). The degree of condensation the carrier-DNA complexes, considerable variability in the
Gene Transfer into Respiratory Epithelial Cells In Vivo 499
_Figure 6. Detection of pIgR ex-
pression in the rat tracheal epithe-
lium and submucosal glands by
immunohistochemical staining.
Tracheal sections from rats were
analyzed for the presence of the
pIgR by immunofluorescence
techniques as described in Meth-
ods, after the animals underwent
transfection with 300 jig of the
plasmidpCMV lacZcomplexed to
the anti-rat SC Fab-based carrier.
Original magnifications of the
photomicrographs are in parenthe-
ses. (a) View of the rat tracheal
section after indirect immunoflu-
orescence staining (x200). (b)
phase contrast view of the same
rat tracheal epithelium (X200).
The apical surface of the airway
epithelium (E) and submucosal
glands (G) are indicated.
level of transgene expression exists. Many of the sources of from the endosomal compartments, which have been effective
variability of this system remain uncertain. in increasing the expression of transgenes in vitro delivered via
Hepatocyte replication, stimulated by partial hepatectomy, other receptors (4, 5). Therefore, the duration and level of
greatly increases the level and persistence of transgene expres- expression reported here most likely represents the minimum
sion introduced by targeting the asialoglycoprotein receptor (8- that can be achieved with this method. Most of the DNA trans-
10), apparently due to the prolonged survival of the transferred ferred into target cells by receptor-mediated endocytosis appears
DNA in cytoplasmic endosomal vesicles (45). In our system to exist as episomes (7, 9), and thus may not persist in the
of targeting epithelial cells, no pharmacologic or physiologic nuclei as the transfected cells divide. The DNA used in these
strategies were employed to disrupt the trafficking of the DNA- experiments did not contain sequences designed to permit the
carrier complexes or increase the release of the foreign DNA transgene to persist in the target cell, either by integration or
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by episomal replication. If the transferred gene fails to persist
in the target cell, repeated treatments will be required. Conse-
quently, the immunologic properties of these DNA-carrier
complexes will need to be investigated. Although the individual
components of the complex are, by themselves, weak immuno-
gens, the intact complex may be quite different.
In summary, the pIgR seems to be a promising receptor to
target to achieve transgene delivery and expression in vivo. The
distribution of this receptor in airway epithelium and the serous
cells of the submucosal glands may be especially useful for
the correction of the genetic defect that results in cystic fibro-
sis (13).
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